【摘要】 为了探讨中晚期肝癌的临床治疗价值,将49例不能接受手术的中晚期肝癌患者分3组采用不同的方法治疗。18例接受单纯放射治疗(RT);18例接受单纯的肝动脉导管化疗栓塞(TACE);13例采用肝动脉导管化疗栓塞加放疗(TACE+RT)。结果49例患者的1、2、3年生存率分别为61.2%、32.6%和14.3%,各组1、2、3年生存率分别为TACE组38.9%、5.6%和0,RT组66.7%、38.9%和16.7%,TACE+RT组84.6%、53.8%和30.8%。TACE组与RT组之间及TACE+RT组与RT组之间差异均无统计学意义,P均>0.05;TACE+RT组与TACE组之间差异有统计学意义,P<0.05。初步研究结果提示,中晚期肝癌在临床治疗上TACE+RT的疗效优于单纯RT及单纯TACE,由此对失去手术机会的中晚期肝癌仍可积极治疗,TACE+RT联合治疗为首选治疗。更多还原

【Abstract】 The objective of this research was to study the value of clinical treatment for 49 cases of unable-surgery middle or advanced stage hepatocellular carcinoma. With different treatment methods after divided into 3 groups, 18 patients were treated with radiation therapy (RT) only; 18 with transhepatic arterial chemoembolization (TACE); 13 with TACE+RT. A total of 49 cases showed the survival rates of 1-,2-,3- year were 61.2%, 32.6% and 14.3%, respectively; 1-,2-,3-,year survival rates were 38.9%, 5.6%, 0, in TACE group; 66.7%, 38.9%, 16.7%, in RT group; 84.6%, 53.8%, 30.8% in TACE + RT group. There was no significant statistic difference between groups of TACE and RT, neither between groups of TACE+ RT and RT, P>0.05; but there was a significant statistic difference between groups TACE+RT and TACE, P<0.05. Primary study indicates that TACE+RT has better therapeutic results than RT or TACE used only in middle or advanced stage hepatocellular carcinoma. TACE+RT combined therapy is more effective, and to is the first selection, than other methods for unable-surgery middle or advanced stage hepatocellular carcinoma.更多还原